Valora Therapeutics, a biotechnology company headquartered in San Diego, California, has closed its seed funding round with an investment of $30 million co-led by life science in investors, Avalon BioVentures, with participation fom Bregua Corporation and TigerGene.

This investment will serve to develop and expand Valora’s AbLec platform, which advances the research and creation of novel immunotherapies. AbLecs can modulate glyco-immune checkpoints by targeting specific cellular sugar molecules; these are important control points in the body’s immune system. This approach provides potential for unique and novel therapies in the areas of oncology and autoimmune diseases.

Valora has established its R&D operations at the Avalon BioVentures Accelerator in San Diego, California, which will provides the start-up with access to a supportive array of biotech experts and resources.